| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | GL002; C11orf30 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human EMSY |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于EMSY抗体的3篇参考文献及其摘要概述：
---
1. **文献名称**：*EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer*
**作者**：Hughes-Davies L, et al.
**摘要**：该研究首次发现EMSY基因与BRCA2通路的关系，揭示了其在散发性乳腺癌和卵巢癌中的扩增现象，并通过抗体检测证实EMSY蛋白与BRCA2相互作用，可能抑制DNA损伤修复功能。
---
2. **文献名称**：*EMSY expression in breast cancer: associations with clinicopathological and molecular parameters*
**作者**：Raouf A, et al.
**摘要**：研究利用EMSY抗体进行免疫组化分析，发现EMSY蛋白在乳腺癌中高表达，并与11q13扩增及不良预后相关，提示其作为潜在生物标志物的价值。
---
3. **文献名称**：*EMSY overexpression disrupts the BRCA2/RAD51 pathway in ovarian cancer*
**作者**：Dansonka-Mieszkowska A, et al.
**摘要**：通过Western blot和免疫荧光技术，研究发现卵巢癌中EMSY过表达会干扰BRCA2/RAD51介导的同源重组修复，导致基因组不稳定性，可能影响化疗敏感性。
---
**备注**：以上文献均基于EMSY抗体的应用展开机制或临床研究，具体实验方法中提及抗体使用(如克隆号、验证数据等)。如需全文，建议通过PubMed或期刊官网检索标题获取。
The EMSY antibody is a research tool targeting the EMSY protein, encoded by the *EMSY* gene located on chromosome 11q13. First identified in 2003. EMSY gained attention due to its interaction with BRCA2. a tumor suppressor critical in DNA repair. EMSY binds to the transactivation domain of BRCA2. potentially inhibiting its function in homologous recombination repair (HRR), a pathway vital for maintaining genomic stability. Overexpression or amplification of *EMSY* has been linked to sporadic breast and ovarian cancers, mirroring phenotypes seen in BRCA2-deficient tumors, earning it the nickname "BRCA2-associated factor."
EMSY antibodies are primarily used to study protein expression, localization, and interaction networks in cancer models. They aid in identifying EMSY's role in transcriptional regulation, chromatin remodeling, and DNA damage response. Clinically, EMSY _expression (detected via IHC or Western blot using specific antibodies) has been explored as a prognostic biomarker, particularly in triple-negative breast cancer and high-grade serous ovarian carcinoma. However, findings remain controversial, partly due to variability in antibody specificity and assay conditions. Recent studies also investigate EMSY's interplay with other oncogenic pathways, such as PI3K/AKT, highlighting its potential as a therapeutic target. Validated EMSY antibodies are crucial for clarifying its dual roles in tumor suppression and oncogenesis, depending on cellular context.
×
